On the Record · Patheon

Patheon acquisitions, on the record

The businesses Patheon bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Irix Pharmaceuticals, Inc. Word for word“• On March 31, 2015, we acquired Irix Pharmaceuticals, Inc., or Irix, a company that specializes in difficult-to-manufacture active pharmaceutical ingredient needs for drugs from early and late development stages through 40 commercial manufacturing, which enhances our service offerings in the DSS segment, for an aggregate purchase price of approximately $161.3 million, which we refer to as the Irix Acquisition.” 10-K for 2016	acquisition	On March 31, 2015	approximately $161.3 million
Agere Pharmaceuticals, Inc. Word for word“• On March 20, 2015, we acquired Agere Pharmaceuticals, Inc., or Agere, a recognized leader in complex solubility technology, to expand our early stage pharmaceutical development capabilities, which enhances our service offerings in the PDS segment, for an aggregate purchase price of approximately $27.1 million, which we refer to as the Agere Acquisition.” 10-K for 2016	acquisition	On March 20, 2015	approximately $27.1 million
Gallus BioPharmaceuticals, LLC Word for word“• On September 29, 2014, we acquired Gallus BioPharmaceuticals, LLC, or Gallus, a leading contract manufacturing company specializing in biologics, which enhances our service offerings in the DSS segment, for a cash purchase price of $257.2 million, which we refer to as the Gallus Acquisition.” 10-K for 2016	acquisition	On September 29, 2014	$257.2 million
DPx Fine Chemicals business Word for word“DFC was sold for a cash purchase price of €179.0 million, which includes an adjustment for working capital.” 10-K for 2016	divestiture	—	€179.0 million
Biosolutions business Word for word“• On July 31, 2015, we sold our Biosolutions business, which produces a variety of microorganisms and anti-effective, enzyme, and pharmaceutical protein products, for approximately €0.3 million.” 10-K for 2016	divestiture	On July 31, 2015	approximately €0.3 million
Banner Pharmacaps entity in Mexico Word for word“• On May 12, 2015, we sold our Banner Pharmacaps entity in Mexico, which manufactures softgel OTC products, for approximately $36.4 million.” 10-K for 2016	divestiture	On May 12, 2015	approximately $36.4 million

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)
2016-10-31	$0

Deal filings since 2016

2017-09-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-05-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-18 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-02-01 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2016-12-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-07-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Patheon’s annual reports (10-K for 2016) and the financial data it files with the SEC, as of 2016-12-23. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.